SAN DIEGO, April 17, 2019 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, today announced that it has garnered news coverage in international media outlet BloombergNews.
An April 16, 2019 article entitled, “Ex-Bond Trader Says Brazil Luring CBD Investment as Demand Grows,” features an interview with Medical Marijuana, Inc. CEO Dr. Stuart Titus discussing how the company’s subsidiary HempMeds® Brasil aims to increase its sales in 2019 and how Medical Marijuana, Inc. sees Brazil as a major investment opportunity.
“According to analysts at New Frontier Data, the cannabis market in Latin America has an estimated current worth of $9.8 billion, with $2.4 billion of that coming directly from Brazil,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We are excited to be at the forefront of this region’s expansion into the cannabis industry and look forward to building on our 2018 successes to expand our Latin American operations even more in 2019.”
The article outlines how cannabidiol (CBD) has been allowed for import in Brazil since 2014 and how Medical Marijuana, Inc. uses European hemp to manufacture CBD products in the U.S. and exports them to Latin American countries such as Brazil, Mexico, Paraguay and Argentina.
HempMeds® Brasil was the first company to receive approval from the National Sanitary Surveillance Agency (Anvisa) to import a CBD-based product. Currently, the company is authorized to supply its products for conductions such as epilepsy, Parkinson’s Disease, chronic pain and multiple sclerosis, under medical prescription. For these indications, the products can be subsidized by the Brazilian government.
Bloomberg News is an international media platform that has over 54 million visitors. It aims to quickly and accurately deliver business and financial information, news and insight around the world. With offices in more than 50 cities and countries, Bloomberg Newscovers financial news stories related to markets, politics, technology, and culture.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer CMW Media